Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Cristino L, Bisogno T, Di Marzo V.

Nat Rev Neurol. 2020 Jan;16(1):9-29. doi: 10.1038/s41582-019-0284-z. Epub 2019 Dec 12. Review.

PMID:
31831863
2.

N-Acyl Amino Acids: Metabolism, Molecular Targets, and Role in Biological Processes.

Battista N, Bari M, Bisogno T.

Biomolecules. 2019 Dec 3;9(12). pii: E822. doi: 10.3390/biom9120822. Review.

3.

Different Routes to Inhibit Fatty Acid Amide Hydrolase: Do All Roads Lead to the Same Place?

Giacovazzo G, Bisogno T, Piscitelli F, Verde R, Oddi S, Maccarrone M, Coccurello R.

Int J Mol Sci. 2019 Sep 11;20(18). pii: E4503. doi: 10.3390/ijms20184503.

4.

Impaired brain endocannabinoid tone in the activity-based model of anorexia nervosa.

Collu R, Scherma M, Piscitelli F, Giunti E, Satta V, Castelli MP, Verde R, Fratta W, Bisogno T, Fadda P.

Int J Eat Disord. 2019 Nov;52(11):1251-1262. doi: 10.1002/eat.23157. Epub 2019 Aug 27.

PMID:
31456239
5.

Role of the Specialized Proresolving Mediator Resolvin D1 in Systemic Lupus Erythematosus: Preliminary Results.

Navarini L, Bisogno T, Margiotta DPE, Piccoli A, Angeletti S, Laudisio A, Ciccozzi M, Afeltra A, Maccarrone M.

J Immunol Res. 2018 Oct 21;2018:5264195. doi: 10.1155/2018/5264195. eCollection 2018.

6.

Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism.

Navarini L, Bisogno T, Mozetic P, Piscitelli F, Margiotta DPE, Basta F, Afeltra A, Maccarrone M.

Int J Biochem Cell Biol. 2018 Jun;99:161-168. doi: 10.1016/j.biocel.2018.04.010. Epub 2018 Apr 12.

PMID:
29655919
7.

Limited Access to a High Fat Diet Alters Endocannabinoid Tone in Female Rats.

Satta V, Scherma M, Piscitelli F, Usai P, Castelli MP, Bisogno T, Fratta W, Fadda P.

Front Neurosci. 2018 Feb 2;12:40. doi: 10.3389/fnins.2018.00040. eCollection 2018.

8.

Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Catani MV, Gasperi V, Bisogno T, Maccarrone M.

Antioxid Redox Signal. 2018 Jul 1;29(1):37-60. doi: 10.1089/ars.2016.6958. Epub 2017 Jul 24. Review.

9.

Lifelong imbalanced LA/ALA intake impairs emotional and cognitive behavior via changes in brain endocannabinoid system.

Zamberletti E, Piscitelli F, De Castro V, Murru E, Gabaglio M, Colucci P, Fanali C, Prini P, Bisogno T, Maccarrone M, Campolongo P, Banni S, Rubino T, Parolaro D.

J Lipid Res. 2017 Feb;58(2):301-316. doi: 10.1194/jlr.M068387. Epub 2016 Nov 30.

10.

2-arachidonoylglycerol levels are increased in leukocytospermia and correlate with seminal macrophages.

Barbonetti A, Bisogno T, Battista N, Piscitelli F, Micillo A, Francavilla S, Maccarrone M, Francavilla F.

Andrology. 2017 Jan;5(1):87-94. doi: 10.1111/andr.12283. Epub 2016 Nov 11.

11.

Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors.

Chiurchiù V, Leuti A, Cencioni MT, Albanese M, De Bardi M, Bisogno T, Centonze D, Battistini L, Maccarrone M.

Pharmacol Res. 2016 Nov;113(Pt A):313-319. doi: 10.1016/j.phrs.2016.09.003. Epub 2016 Sep 8.

PMID:
27616551
12.

Type-2 cannabinoid receptors in neurodegeneration.

Bisogno T, Oddi S, Piccoli A, Fazio D, Maccarrone M.

Pharmacol Res. 2016 Sep;111:721-730. doi: 10.1016/j.phrs.2016.07.021. Epub 2016 Jul 20. Review.

PMID:
27450295
13.

The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases.

Coccurello R, Bisogno T.

Expert Rev Clin Pharmacol. 2016 Oct;9(10):1351-1362. doi: 10.1080/17512433.2016.1209111. Epub 2016 Jul 19.

PMID:
27373318
14.

Assay of DAGLα/β Activity.

Bisogno T.

Methods Mol Biol. 2016;1412:149-56. doi: 10.1007/978-1-4939-3539-0_16.

PMID:
27245901
15.

Endocannabinoid signaling and its regulation by nutrients.

Bisogno T, Maccarrone M.

Biofactors. 2014 Jul-Aug;40(4):373-80. doi: 10.1002/biof.1167. Epub 2014 Apr 21. Review.

PMID:
24753395
16.

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.

Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M, Sagredo O, Di Marzo V, Fernández-Ruiz J.

Cell Death Dis. 2013 Oct 17;4:e862. doi: 10.1038/cddis.2013.387.

17.

Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.

Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G, Baker D.

Mult Scler. 2013 Dec;19(14):1896-904. doi: 10.1177/1352458513485982. Epub 2013 Apr 26.

PMID:
23625705
18.

Latest advances in the discovery of fatty acid amide hydrolase inhibitors.

Bisogno T, Maccarrone M.

Expert Opin Drug Discov. 2013 May;8(5):509-22. doi: 10.1517/17460441.2013.780021. Epub 2013 Mar 14. Review.

PMID:
23488865
19.

A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Bisogno T, Mahadevan A, Coccurello R, Chang JW, Allarà M, Chen Y, Giacovazzo G, Lichtman A, Cravatt B, Moles A, Di Marzo V.

Br J Pharmacol. 2013 Jun;169(4):784-93. doi: 10.1111/bph.12013.

20.

Novel bioactive metabolites of dipyrone (metamizol).

Rogosch T, Sinning C, Podlewski A, Watzer B, Schlosburg J, Lichtman AH, Cascio MG, Bisogno T, Di Marzo V, Nüsing R, Imming P.

Bioorg Med Chem. 2012 Jan 1;20(1):101-7. doi: 10.1016/j.bmc.2011.11.028. Epub 2011 Nov 25.

21.

Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice.

Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S, Cohn JS, Griinari M, Banni S, Di Marzo V.

Nutr Metab (Lond). 2011 Jul 13;8(1):51. doi: 10.1186/1743-7075-8-51.

22.

Endocannabinoids generated by Ca2+ or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase.

Zhang L, Wang M, Bisogno T, Di Marzo V, Alger BE.

PLoS One. 2011 Jan 28;6(1):e16305. doi: 10.1371/journal.pone.0016305.

23.

Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V.

Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x.

24.

Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.

Bisogno T, Di Marzo V.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):564-73. Review.

PMID:
20632970
25.

Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus.

Min R, Testa-Silva G, Heistek TS, Canto CB, Lodder JC, Bisogno T, Di Marzo V, Brussaard AB, Burnashev N, Mansvelder HD.

J Neurosci. 2010 Feb 17;30(7):2710-5. doi: 10.1523/JNEUROSCI.BC-3622-09.2010.

26.

Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase.

Saturnino C, Petrosino S, Ligresti A, Palladino C, De Martino G, Bisogno T, Di Marzo V.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1210-3. doi: 10.1016/j.bmcl.2009.11.134. Epub 2009 Dec 4.

PMID:
20022504
27.

Protective role of palmitoylethanolamide in contact allergic dermatitis.

Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D'Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V.

Allergy. 2010 Jun 1;65(6):698-711. doi: 10.1111/j.1398-9995.2009.02254.x. Epub 2009 Nov 11.

PMID:
19909294
28.

A gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up.

Cobellis G, Ricci G, Cacciola G, Orlando P, Petrosino S, Cascio MG, Bisogno T, De Petrocellis L, Chioccarelli T, Altucci L, Fasano S, Meccariello R, Pierantoni R, Ledent C, Di Marzo V.

Biol Reprod. 2010 Feb;82(2):451-8. doi: 10.1095/biolreprod.109.079210. Epub 2009 Oct 7.

PMID:
19812302
29.

The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine.

Hu SS, Bradshaw HB, Benton VM, Chen JS, Huang SM, Minassi A, Bisogno T, Masuda K, Tan B, Roskoski R Jr, Cravatt BF, Di Marzo V, Walker JM.

Prostaglandins Leukot Essent Fatty Acids. 2009 Oct;81(4):291-301. doi: 10.1016/j.plefa.2009.05.026. Epub 2009 Jun 30.

30.

Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats.

Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Sanna F, Bisogno T, Uda S, Collu M, Bruheim I, Di Marzo V, Banni S.

J Nutr. 2009 Aug;139(8):1495-501. doi: 10.3945/jn.109.104844. Epub 2009 Jun 23.

PMID:
19549757
31.

The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis.

Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T, Geremia R, De Petrocellis L, Di Marzo V.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11131-6. doi: 10.1073/pnas.0812789106. Epub 2009 Jun 18.

32.

Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol.

Bisogno T, Burston JJ, Rai R, Allarà M, Saha B, Mahadevan A, Razdan RK, Wiley JL, Di Marzo V.

ChemMedChem. 2009 Jun;4(6):946-50. doi: 10.1002/cmdc.200800442.

PMID:
19266526
33.

The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons.

Marinelli S, Pacioni S, Bisogno T, Di Marzo V, Prince DA, Huguenard JR, Bacci A.

J Neurosci. 2008 Dec 10;28(50):13532-41. doi: 10.1523/JNEUROSCI.0847-08.2008.

34.

Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo.

Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, Maione S, Di Marzo V; Endocannabinoid Research Group.

Biochim Biophys Acta. 2009 Jan;1791(1):53-60. doi: 10.1016/j.bbalip.2008.10.007. Epub 2008 Nov 5.

PMID:
19027877
35.

Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide.

De Petrocellis L, Deva R, Mainieri F, Schaefer M, Bisogno T, Ciccoli R, Ligresti A, Hill K, Nigam S, Appendino G, Di Marzo V.

J Lipid Res. 2009 Apr;50(4):658-66. doi: 10.1194/jlr.M800337-JLR200. Epub 2008 Nov 17.

36.

The endocannabinoid system is modulated in response to spinal cord injury in rats.

Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C, Di Marzo V, Molina-Holgado E.

Neurobiol Dis. 2009 Jan;33(1):57-71. doi: 10.1016/j.nbd.2008.09.015. Epub 2008 Sep 30.

PMID:
18930143
37.

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.

Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V.

J Med Chem. 2008 Nov 13;51(21):6970-9. doi: 10.1021/jm800978m. Epub 2008 Oct 3.

PMID:
18831576
38.

The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.

Bisogno T, Di Marzo V.

Curr Pharm Des. 2008;14(23):2299-3305. Review.

PMID:
18781980
39.

Novel sterically hindered cannabinoid CB1 receptor ligands.

Urbani P, Cascio MG, Ramunno A, Bisogno T, Saturnino C, Di Marzo V.

Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. doi: 10.1016/j.bmc.2008.06.001. Epub 2008 Jun 7.

PMID:
18579386
40.

Endogenous cannabinoids: structure and metabolism.

Bisogno T.

J Neuroendocrinol. 2008 May;20 Suppl 1:1-9. doi: 10.1111/j.1365-2826.2008.01676.x. Review.

PMID:
18426492
41.

Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders.

Bisogno T, Di Marzo V.

Pharmacol Res. 2007 Nov;56(5):428-42. Epub 2007 Sep 8.

PMID:
17933549
42.

Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.

Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V.

Neurochem Int. 2008 Jan;52(1-2):307-13. Epub 2007 Jul 4.

PMID:
17664017
43.

Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology.

Di Marzo V, Bisogno T, De Petrocellis L.

Chem Biol. 2007 Jul;14(7):741-56. Review.

44.

Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro.

Iuvone T, Esposito G, De Filippis D, Bisogno T, Petrosino S, Scuderi C, Di Marzo V, Steardo L; Endocannabinoid Research Group.

J Mol Med (Berl). 2007 Dec;85(12):1379-92. Epub 2007 Jul 17.

PMID:
17639288
45.

Metabolically labile cannabinoid esters: a 'soft drug' approach for the development of cannabinoid-based therapeutic drugs.

Minutolo F, Cascio MG, Carboni I, Bisogno T, Prota G, Bertini S, Digiacomo M, Bifulco M, Di Marzo V, Macchia M.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4878-81. Epub 2007 Jun 20.

PMID:
17604171
46.

Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.

Brizzi A, Cascio MG, Brizzi V, Bisogno T, Dinatolo MT, Martinelli A, Tuccinardi T, Di Marzo V.

Bioorg Med Chem. 2007 Aug 15;15(16):5406-16. Epub 2007 May 31.

PMID:
17561406
47.

Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats.

Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V.

Neuropharmacology. 2007 Feb;52(2):415-22. Epub 2006 Sep 29.

PMID:
17011598
48.

Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol.

Szabo B, Urbanski MJ, Bisogno T, Di Marzo V, Mendiguren A, Baer WU, Freiman I.

J Physiol. 2006 Nov 15;577(Pt 1):263-80. Epub 2006 Sep 14.

49.

In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.

Cascio MG, Bisogno T, Palazzo E, Thomas A, van der Stelt M, Brizzi A, de Novellis V, Marabese I, Ross R, van de Doelen T, Brizzi V, Pertwee R, Maione S, Di Marzo V.

Br J Pharmacol. 2006 Oct;149(4):431-40. Epub 2006 Sep 4.

50.

Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes.

Kamprath K, Marsicano G, Tang J, Monory K, Bisogno T, Di Marzo V, Lutz B, Wotjak CT.

J Neurosci. 2006 Jun 21;26(25):6677-86.

Supplemental Content

Loading ...
Support Center